Diagnostic and Prognostic Biomarkers for Myocardial Infarction

Wu, Yuping; Pan, Nana; An, Yi; Xu, Mengyuan; Tan, Lijuan; Zhang, Lijuan

doi:10.3389/fcvm.2020.617277

Cited by 51 publications

(43 citation statements)

References 150 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, these two datasets had only four and eight experimental group samples, which may cause some errors and bias. Currently, the urgent need for early detection, early diagnosis, and timely treatment of MI for the relatively low sensitivity and specificity cannot be met by existing serum markers (cTn, MB, and CK-MB) [ 34 ]. It was revealed in the results of this study that the area under the ROC curve was over 0.5, indicating that TLR2 expression has a particular diagnostic value for MI, and the total AUC of the sROC curve was 0.78.…”

Section: Discussionmentioning

confidence: 99%

Clinical assessment and molecular mechanism of the upregulation of Toll-like receptor 2 (TLR2) in myocardial infarction

Yan

Dong

et al. 2022

BMC Cardiovasc Disord

View full text Add to dashboard Cite

Objective The prevalence and mortality of cardiovascular diseases remain ranked first worldwide. Myocardial infarction (MI) is the central cause of death from cardiovascular diseases, seriously endangering human health. The clinical implication of toll-like receptor 2 (TLR2) remains contradictory, and its mechanism is still unknown. Hence, the objective of this study was to elucidate the clinical value and molecular mechanism of TLR2 in MI. Methods All high-throughput datasets and eligible literature were screened, and the expression levels of TLR2 were collected from the MI. The integrated expression level of TLR2 was displayed by calculating the standardized mean difference (SMD) and the area under the curve (AUC) of the summary receiver operating characteristic curve (sROC). The related TLR2 genes were sent for pathway analyses by gene ontology (GO), Kyoto encyclopedia of genes and genome (KEGG), and disease ontology (DO). Single-cell RNA-seq was applied to ascertain the molecular mechanism of TLR2 in MI. Results Nine microarrays and four reported data were available to calculate the comprehensive expression level of TLR2 in MI, including 325 cases of MI and 306 cases of controls. The SMD was 2.55 (95% CI = 1.35–3.75), and the AUC was 0.76 (95% CI = 0.72–0.79), indicating the upregulation of TLR2 in MI. The related TLR2 genes were primarily enriched in the pathways of atherosclerosis, arteriosclerotic cardiovascular disease, and arteriosclerosis, suggesting the clinical role of TLR2 in the progression of MI. Afterward, TLR2 was upregulated in myeloid cells in MI. Conclusions TLR2 may have a crucial role in progressing from coronary atherosclerosis to MI. The upregulation of TLR2 may have a favorable screening value for MI.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical assessment and molecular mechanism of the upregulation of Toll-like receptor 2 (TLR2) in myocardial infarction

Yan

Dong

et al. 2022

BMC Cardiovasc Disord

View full text Add to dashboard Cite

show abstract

“…New risk markers can significantly improve survival of patients who are at high risk despite reperfusion therapy that others have demonstrated for the identification of subgroups of patients at greater risk. 11 Right ventricular (RV) dysfunction is a powerful risk marker after acute myocardial infarction (MI). Reliable data on RV damage using cardiac magnetic resonance imaging (MRI) are scarce.…”

Section: Discussionmentioning

confidence: 99%

Correlation between Right Ventricular Function with Revascularization Time and 30-day Mortality in ST-Elevation Myocardial Infarction Patients Underwent Right Coronary Artery Intervention

Luntungan

Djafar

Panda

et al. 2022

eCL

View full text Add to dashboard Cite

Abstracts: Right ventricular (RV) function provides strong prognostic information in patients treated with primary percutaneous coronary intervention (PCI) due to myocardial infarction. Longitudinal RV systolic function can be assessed by the measurement of the tricuspid annular plane systolic excursion (TAPSE). This study aimed to evaluate the correlation between TAPSE and revascularization time with 30-day mortality using TIMI risk score in patients presenting STEMI who underwent revascularization of right coronary artery (RCA). This was a descriptive amd analytical study. Data were collected from iSTEMI Registry database which consisted of 49 STEMI patients undergoing PCI in RCA and TAPSE measurement at Prof. Dr. R. D. Kandou General Hospital from October 3rd, 2018 to July 28th, 2019. Echocardiographic examination was done within 48 hours of hospitalization. A descriptive analysis and bivariate correlation with Spearman’s rho were applied between given variables. P-value of <0.05 was considered to be statistically significant. The results showed that the mean age of the patients was 57.92 10.345 years old and 79.2% were male. The mean TAPSE measurement was 18.51 mm +/- 3.63 mm. The median revascularization time was 357.5 minutes while median TIMI score was 4. Shorter treatment time (p=0.708) and lower TIMI score (p=0.923) were not associated with better right ventricular function measured with TAPSE in patients undergoing RCA intervention. In conclusion, right ventricular function is not associated with revascularization time and thirty days mortality in patients presenting with ST-elevation acute myocardial infarction involving right coronary artery.Keywords: tricuspid annular plane systolic excursion; revascularization time; right coronary artery; ST-elevation myocardial infarction

show abstract

“…In a previous study using a rat model of doxorubicin-induced cardiotoxicity, treatment with α-mangostin (100 and 200 mg/kg) was suggested to improve electrocardiograph recordings, heart/body weight ratio and histological structures, increase systolic blood pressure, decrease MdA levels, improved the GSH level and normalize creatine kinase-MB (cK-MB) levels and lactate dehydrogenase (LdH) compared to doxorubicin-treated (dOX) rats (95). cK-MB detection in serum is a sensitive indicator in the early stages of cardiac damage, whereas LdH levels will increase when further cardiac damage occurs (96,97). As previously demonstrated, α-mangostin (100 mg/kg) reduced the ratio of Bax/Bcl-2 as compared to dOX in heart tissues.…”

Section: Cardioprotective and Anti-atherogenic Effects Of α-Mangostinmentioning

confidence: 99%

The metabolic and molecular mechanisms of α‑mangostin in cardiometabolic disorders (Review)

et al. 2022

View full text Add to dashboard Cite

α-mangostin is a xanthone predominantly encountered in Garcinia mangostana. Extensive research has been carried out concerning the effects of this compound on various diseases, including obesity, cancer and metabolic disorders. The present review suggests that α-mangostin exerts promising anti-obesity, hepatoprotective, antidiabetic, cardioprotective, antioxidant and anti-inflammatory effects on various pathways in cardiometabolic diseases. The anti-obesity effects of α-mangostin include the reduction of body weight and adipose tissue size, the increase in fatty acid oxidation, the activation of hepatic AMP-activated protein kinase and Sirtuin-1, and the reduction of peroxisome proliferator-activated receptor γ expression. Hepatoprotective effects have been revealed, due to reduced fibrosis through transforming growth factor-β 1 pathways, reduced apoptosis and steatosis through reduced sterol regulatory-element binding proteins expression. The antidiabetic effects include decreased fasting blood glucose levels, improved insulin sensitivity and the increased expression of GLUT transporters in various tissues. cardioprotection is exhibited through the restoration of cardiac functions and structure, improved mitochondrial functions, the promotion of M2 macrophage populations, reduced endothelial and cardiomyocyte apoptosis and fibrosis, and reduced acid sphingomyelinase activity and ceramide depositions. The antioxidant effects of α-mangostin are mainly related to the modulation of antioxidant enzymes, the reduction of oxidative stress markers, the reduction of oxidative damage through a reduction in Sirtuin 3 expression mediated by phosphoinositide 3-kinase/protein kinase B/peroxisome proliferator-activated receptor-γ coactivator-1α signaling pathways, and to the increase in Nuclear factor-erythroid factor 2-related factor 2 and heme oxygenase-1 expression levels. The anti-inflammatory effects of α-mangostin include its modulation of nuclear factor-κB related pathways, the suppression of mitogen-activated protein kinase activation, increased macrophage polarization to M2, reduced inflammasome occurrence, increased Sirtuin 1 and 3 expression, the reduced expression of inducible nitric oxide synthase, the production of nitric oxide and prostaglandin E2, the reduced expression of Toll-like receptors and reduced proinflammatory cytokine levels. These effects demonstrate that α-mangostin may possess the properties required for a suitable candidate compound for the management of cardiometabolic diseases. Contents1. Introduction 2. Anti-obesity effects of α-mangostin 3. Antidiabetic effects of α-mangostin 4. Anti-steatotic and hepatoprotective effects of α-mangostin 5. cardioprotective and anti-atherogenic effects of α-mangostin 6. Antioxidant effects of α-mangostin 7. Anti-inflammatory effects of α-mangostin 8. Toxicity and bioavailability of α-mangostin 9. Future perspectives 10. conclusions

show abstract

Diagnostic and Prognostic Biomarkers for Myocardial Infarction

Cited by 51 publications

References 150 publications

Clinical assessment and molecular mechanism of the upregulation of Toll-like receptor 2 (TLR2) in myocardial infarction

Clinical assessment and molecular mechanism of the upregulation of Toll-like receptor 2 (TLR2) in myocardial infarction

Correlation between Right Ventricular Function with Revascularization Time and 30-day Mortality in ST-Elevation Myocardial Infarction Patients Underwent Right Coronary Artery Intervention

The metabolic and molecular mechanisms of α‑mangostin in cardiometabolic disorders (Review)

Contact Info

Product

Resources

About